Healthcare analysts weighed in today on small biopharmaceutical firms Relypsa Inc (NASDAQ:RLYP) and Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), following meeting with management and Phase II clinical trial update, respectively. Below are the commentaries along with current ratings and price targets.
BTIG analyst Tim Chiang reiterated a Buy rating on shares of Relypsa with a price target of $45, following recent meeting with the management team in NYC.
Chiang noted, “CEO John Orwin and CFO Kristine Ball highlighted the Co’s ongoing launch of Veltassa (for the treatment of hyperkalemia), with its 133-person sales force mainly targeting specialists in the nephrology and cardiology segments. While the launch is still in its early days, we believe physician interest is strong, as Veltassa is the first new treatment to be approved in over 50 years. Overall, we came away positive from our meeting. For additional details, please contact your BTIG sales person. We believe recent weakness in the shares provides investors with an attractive buying opportunity.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Tim Chiang has a yearly average return of 0% and a 43.2% success rate. Chiang has a -37.7% average return when recommending RLYP, and is ranked #1833 out of 3556 analysts.
As of this writing, all the 9 analysts polled by TipRanks, in the last 3 months, rate Relypsa stock a Buy. With a return potential of 206%, the stock’s consensus target price stands at $51.38.
Rexahn Pharmaceuticals, Inc.
FBR Capital analyst Vernon Bernardino reiterated an Outperform rating on shares of Rexahn with a $3.00 price target, after the company announced that it has initiated enrollment for Stage 2 of an ongoing Phase IIa trial of Archexin in combination with everolimus for the treatment of metastatic renal cell carcinoma.
Bernardino noted, “The Phase IIa randomized, open-label, two-arm dose expansion study will randomize about 30 RCC patients in a 2:1 ratio to receive either 250 mg/m2/day Archexin combined with 10mg everolimus, or 10mg everolimus alone. The trial’s primary endpoint in Stage 2 will measure the percentage of progression free patients after eight treatment cycles, with tumor progression assessed after every two treatment cycles. We expect to see prolonged progressionfree survival from this Archexin combination given three patients reported stable disease for 383, 191, and 122 days in Stage 1, and two patients reported tumor burden reduction of 16% and 36% as of January 6, 2016.”
According to TipRanks.com, analyst Vernon Bernardino has a yearly average return of -40.5% and a 10.1% success rate. Bernardino has a -47.6% average return when recommending RNN, and is ranked #3549 out of 3556 analysts.